

Andrew Mark Taylor

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2950112/publications.pdf>

Version: 2024-02-01

72
papers

3,469
citations

293460

24
h-index

156644

58
g-index

72
all docs

72
docs citations

72
times ranked

4694
citing authors

#	ARTICLE	IF	CITATIONS
1	The impact of COVID-19 on antipsychotic prescriptions for patients with schizophrenia in Australia. Australian and New Zealand Journal of Psychiatry, 2022, 56, 642-647.	1.3	4
2	Antipsychotic utilisation and persistence in Australia: A nationwide 5-year study. Australian and New Zealand Journal of Psychiatry, 2022, 56, 1155-1163.	1.3	6
3	Deltoid versus gluteal: Which intramuscular injection site do mental health patients prefer?. Australian and New Zealand Journal of Psychiatry, 2021, 55, 734-735.	1.3	3
4	Synthesis of a gemcitabine-modified phospholipid and its subsequent incorporation into a single microbubble formulation loaded with paclitaxel for the treatment of pancreatic cancer using ultrasound-targeted microbubble destruction. European Journal of Pharmaceutics and Biopharmaceutics, 2021, 165, 374-382.	2.0	12
5	A single microbubble formulation carrying 5-fluorouridine, Irinotecan and oxaliplatin to enable FOLFIRINOX treatment of pancreatic and colon cancer using ultrasound targeted microbubble destruction. Journal of Controlled Release, 2021, 338, 358-366.	4.8	18
6	Sonodynamic therapy complements PD-L1 immune checkpoint inhibition in a murine model of pancreatic cancer. Cancer Letters, 2021, 517, 88-95.	3.2	25
7	Check the effects: systematic assessment of antipsychotic side-effects in an inpatient cohort. Therapeutic Advances in Psychopharmacology, 2020, 10, 204512532095711.	1.2	11
8	Are we getting any better at staying better? The long view on relapse and recovery in first episode nonaffective psychosis and schizophrenia. Therapeutic Advances in Psychopharmacology, 2019, 9, 204512531987003.	1.2	32
9	Shared decision-making in psychiatry: a study of patient attitudes. Australasian Psychiatry, 2018, 26, 478-481.	0.4	16
10	Going the distance: reviewing antipsychotic depot or long-acting injectable treatments in Australasia. Australasian Psychiatry, 2018, 26, 303-306.	0.4	1
11	The Southampton Consensus Guidelines for Laparoscopic Liver Surgery. Annals of Surgery, 2018, 268, 11-18.	2.1	488
12	The outcomes of home treatment for schizophrenia. BJPsych Bulletin, 2018, 42, 238-242.	0.7	5
13	A stitch in time: 3-monthly long-acting injectable paliperidone palmitate in schizophrenia. Therapeutic Advances in Psychopharmacology, 2017, 7, 231-233.	1.2	5
14	The outcomes of home treatment for borderline personality disorder. BJPsych Bulletin, 2016, 40, 306-309.	0.7	7
15	Invited commentary on NICE v. SIGN on psychosis and schizophrenia. British Journal of Psychiatry, 2016, 208, 320-321.	1.7	1
16	Effectiveness of long-acting antipsychotics in clinical practice: 2. Effects of antipsychotic polypharmacy on risperidone long-acting injection and zuclopenthixol decanoate. Therapeutic Advances in Psychopharmacology, 2016, 6, 66-76.	1.2	9
17	Community treatment orders and reduced time in hospital: a nationwide study, 2007-2012. BJPsych Bulletin, 2016, 40, 124-126.	0.7	15
18	Effectiveness of long-acting antipsychotics in clinical practice : 1. A retrospective, 18-month follow up and comparison between paliperidone palmitate, risperidone long-acting injection and zuclopenthixol decanoate. Therapeutic Advances in Psychopharmacology, 2016, 6, 22-32.	1.2	13

#	ARTICLE	IF	CITATIONS
19	Authors' reply. British Journal of Psychiatry, 2015, 207, 561-561.	1.7	0
20	<i>“First do no harm.” A systematic review of the prevalence and management of antipsychotic adverse effects. Journal of Psychopharmacology, 2015, 29, 353-362.	2.0	165
21	The Student Perception of Wellbeing Questionnaire: Preliminary Investigation into its Psychometric Properties. International Journal of Disability Development and Education, 2015, 62, 99-115.	0.6	2
22	Guidance on switching away from Piportil Depot® (pipotiazine palmitate) injection. British Journal of Psychiatry, 2015, 206, 521-521.	1.7	3
23	NICE CG178 <i>Psychosis and Schizophrenia in Adults: Treatment and Management</i> “ an evidence-based guideline?. British Journal of Psychiatry, 2015, 206, 357-359.	1.7	62
24	Glasgow Antipsychotic Side-effects Scale for Clozapine “ Development and validation of a clozapine-specific side-effects scale. Schizophrenia Research, 2015, 168, 505-513.	1.1	46
25	Authors' reply. British Journal of Psychiatry, 2015, 207, 271-271.	1.7	0
26	Socioeconomic status and prescribing for schizophrenia: analysis of 3200 cases from the Glasgow Psychosis Clinical Information System (PsyCIS). Psychiatric Bulletin (2014), 2014, 38, 54-57.	0.4	9
27	NICE CG178 on psychosis - an evidence-based guideline?. The Prescriber, 2014, 25, 6-8.	0.1	1
28	Acute Pancreatitis Secondary to an Incarcerated Paraoesophageal Hernia: A Rare Cause for a Common Problem. Clinical Medicine Insights: Case Reports, 2014, 7, CCRP.S13079.	0.3	13
29	How to compare doses of different antipsychotics: A systematic review of methods. Schizophrenia Research, 2013, 149, 141-148.	1.1	78
30	Early death in those previously hospitalised for mental healthcare in Scotland: a nationwide cohort study, 1986“2010. BMJ Open, 2013, 3, e002768.	0.8	41
31	Should long-acting (depot) antipsychotics be used in early schizophrenia? A systematic review. Australian and New Zealand Journal of Psychiatry, 2013, 47, 624-630.	1.3	53
32	Advances in the understanding and challenges facing the management of first-episode schizophrenia. Journal of Psychopharmacology, 2012, 26, 3-5.	2.0	1
33	Examining the effectiveness of antipsychotic medication in first-episode psychosis. Journal of Psychopharmacology, 2012, 26, 27-32.	2.0	19
34	Antipsychotics and Abnormal Liver Function Tests. Clinical Neuropharmacology, 2012, 35, 244-253.	0.2	51
35	Mortality in Schizophrenia. Journal of Psychopharmacology, 2012, 26, 1285-1285.	2.0	4
36	Quantifying the RR of harm to self and others from substance misuse: results from a survey of clinical experts across Scotland. BMJ Open, 2012, 2, e000774.	0.8	28

#	ARTICLE	IF	CITATIONS
37	Five simple questions to predict violence in psychiatric patients. <i>The Psychiatrist</i> , 2012, 36, 157-157.	0.3	0
38	Community compulsion in Scotland: a descriptive analysis. <i>The Psychiatrist</i> , 2012, 36, 205-207.	0.3	3
39	A Nationwide Cohort Study of Oral and Depot Antipsychotics After First Hospitalization for Schizophrenia. <i>American Journal of Psychiatry</i> , 2011, 168, 603-609.	4.0	552
40	The place of observational studies in assessing the effectiveness of depot antipsychotics. <i>Schizophrenia Research</i> , 2011, 131, 260-261.	1.1	21
41	The adverse consequences of mephedrone use: a case series. <i>The Psychiatrist</i> , 2011, 35, 203-205.	0.3	24
42	Numbers-needed-to-treat analysis: an explanation using antipsychotic trials in schizophrenia. <i>Advances in Psychiatric Treatment</i> , 2011, 17, 63-71.	0.6	6
43	Medication adherence and patient choice in mental health. <i>British Journal of Hospital Medicine (London, England: 2005)</i> , 2011, 72, 6-7.	0.2	3
44	Impact of crisis resolution and home treatment services on user experience and admission to psychiatric hospital. <i>The Psychiatrist</i> , 2011, 35, 106-110.	0.3	45
45	What makes a good psychiatrist?. <i>The Psychiatrist</i> , 2011, 35, 75-75.	0.3	2
46	Clozapine: dangerous orphan or neglected friend?. <i>British Journal of Psychiatry</i> , 2011, 198, 247-249.	1.7	57
47	Crisis resolution and home treatment teams and intensive home treatment teams are worthwhile "but not everywhere". <i>The Psychiatrist</i> , 2011, 35, 276-276.	0.3	0
48	Resolution and remission in schizophrenia: getting well and staying well. <i>Advances in Psychiatric Treatment</i> , 2010, 16, 86-95.	0.6	10
49	Community treatment orders and their use in the UK. <i>Advances in Psychiatric Treatment</i> , 2010, 16, 260-262.	0.6	8
50	Review: Mortality in schizophrenia: a measurable clinical endpoint. <i>Journal of Psychopharmacology</i> , 2010, 24, 17-25.	2.0	163
51	Understanding "significant impaired decision-making ability"™ with regard to treatment for mental disorder: an empirical analysis. <i>The Psychiatrist</i> , 2010, 34, 239-242.	0.3	5
52	Comparison of the effectiveness of depot antipsychotics in routine clinical practice. <i>The Psychiatrist</i> , 2010, 34, 273-279.	0.3	11
53	Review: Suicide and schizophrenia: a systematic review of rates and risk factors. <i>Journal of Psychopharmacology</i> , 2010, 24, 81-90.	2.0	653
54	The trouble with . <i>Psychiatric Bulletin</i> , 2009, 33, 396-396.	0.3	2

#	ARTICLE	IF	CITATIONS
55	First-generation antipsychotic long-acting injections <i>v</i>. oral antipsychotics in schizophrenia: Systematic review of randomised controlled trials and observational studies. British Journal of Psychiatry, 2009, 195, s20-s28.	1.7	89
56	Cognitive Training, Conflict Resolution and Exercise: Effects on Young Adolescents' Wellbeing. Australian Journal of Guidance and Counselling, 2009, 19, 131-149.	0.5	7
57	Attitudes of patients and mental health staff to antipsychotic long-acting injections: Systematic review. British Journal of Psychiatry, 2009, 195, s43-s50.	1.7	87
58	Antipsychotic long-acting injections: Mind the gap. British Journal of Psychiatry, 2009, 195, s1-s4.	1.7	61
59	Comparing the Effectiveness of Aripiprazole and Quetiapine in Schizophrenia and Related Psychoses. Journal of Clinical Psychiatry, 2009, 70, 692-698.	1.1	7
60	Comparing the Use and Discontinuation of Antipsychotics in Clinical Practice. Journal of Clinical Psychiatry, 2008, 69, 240-245.	1.1	38
61	Familial liability to schizophrenia and premorbid adjustment. British Journal of Psychiatry, 2007, 191, 260-261.	1.7	16
62	Outcome of acute psychiatric in-patient care where there are no crisis or home treatment teams. Psychiatric Bulletin, 2007, 31, 387-390.	0.3	0
63	Intramuscular Olanzapine â€œ a UK case series of early cases. Annals of General Psychiatry, 2007, 6, 11.	1.2	9
64	Antipsychotics preferred by mental health professionals. Psychiatric Bulletin, 2007, 31, 272-272.	0.3	2
65	Are you addicted to your â€œcrackberryâ€?. BMJ: British Medical Journal, 2007, 334, 241-241.	2.4	0
66	The psychological impact of September 11 terrorism on Australian inpatients. Australasian Psychiatry, 2004, 12, 253-255.	0.4	12
67	Brain Volumes in Adult Survivors of Very Low Birth Weight: A Sibling-Controlled Study. Pediatrics, 2004, 114, 367-371.	1.0	96
68	Hippocampal volume in familial and nonfamilial schizophrenic probands and their unaffected relatives. Biological Psychiatry, 2003, 53, 562-570.	0.7	72
69	EXPLORING THE COMPLEXITY OF COMPLIANCE IN SCHIZOPHRENIA. Issues in Mental Health Nursing, 2002, 23, 513-528.	0.6	39
70	Hippocampal volume reduction in schizophrenia: effects of genetic risk and pregnancy and birth complications. Biological Psychiatry, 1999, 46, 697-702.	0.7	121
71	Tardive dyskinesia as a risk factor for negative symptoms. British Journal of Psychiatry, 1994, 164, 700-701.	1.7	0
72	Neuroleptics, oestrogen, post-partum psychiatric disturbance and movement disorder: a case report. Journal of Psychopharmacology, 1994, 8, 134-135.	2.0	1